| ACAD |
ACADIA Pharmaceuticals Inc. |
72%
|
1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency … |
| ACAD |
ACADIA Pharmaceuticals Inc. |
72%
|
Reciprocal relationship from ACAD graph: Reciprocal relationship from GHRS graph: 1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our asse… |
| ADCT |
ADC Therapeutics SA |
72%
|
1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency … |
| ADCT |
ADC Therapeutics SA |
72%
|
Reciprocal relationship from ADCT graph: Reciprocal relationship from GHRS graph: 1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our asse… |
| GNMSF |
Genmab A/S |
72%
|
Reciprocal relationship from GNMSF graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from GNMS… |
| GNMSF |
Genmab A/S |
72%
|
1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency … |
| MS-PE |
Morgan Stanley |
72%
|
Reciprocal relationship from MS-PE graph: Reciprocal relationship from GHRS graph: 1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our ass… |
| MS-PK |
Morgan Stanley |
72%
|
1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency … |
| ZLDPF |
Zealand Pharma A/S |
72%
|
1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency … |
| ZLDPF |
Zealand Pharma A/S |
72%
|
Reciprocal relationship from ZLDPF graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from ZLDPF graph: Reciprocal relationship from GHRS graph: 1 million for the year ended Dece… |
| ARDAGH-GROUP |
ARDAGH-GROUP |
62%
|
1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency … |
| ARDX |
Ardelyx, Inc. |
62%
|
Reciprocal relationship from ARDX graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from ARDX graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from ARDX g… |
| BVF2-BVF-PARTNERS-OS-LTD |
BVF2-BVF-PARTNERS-OS-LTD |
62%
|
ion of outstanding options, (4) make payment of a cash settlement to the participants equal (per share) to the amount to be paid for one share under the agreement of merger or takeover, or (5) vary t… |
| COMPANY-GH-RESEARCH-PLC |
COMPANY-GH-RESEARCH-PLC |
62%
|
d reduce the earnings per share, which could have a material adverse effect on the price of shares. We may be at an increased risk of securities class action litigation. Historically, securities clas… |
| CONTINGENCIES-THE-GROUP |
CONTINGENCIES-THE-GROUP |
62%
|
ver which all of the specified vesting conditions are to be satisfied. Share capital and additional paid-in capital Share capital Share capital represents the nominal value of outstanding shares (see… |
| FMR-LLC |
FMR-LLC |
62%
|
ion of outstanding options, (4) make payment of a cash settlement to the participants equal (per share) to the amount to be paid for one share under the agreement of merger or takeover, or (5) vary t… |
| GH-RESEARCH-IRELAND-LIMITED |
GH-RESEARCH-IRELAND-LIMITED |
62%
|
d reduce the earnings per share, which could have a material adverse effect on the price of shares. We may be at an increased risk of securities class action litigation. Historically, securities clas… |
| GH-RESEARCH-IRELAND-LIMITED-GH-RESEARCH-IRELAND- |
GH-RESEARCH-IRELAND-LIMITED-GH-RESEARCH-IRELAND- |
62%
|
d reduce the earnings per share, which could have a material adverse effect on the price of shares. We may be at an increased risk of securities class action litigation. Historically, securities clas… |
| GH-RESEARCH-LIMITED-GH-RESEARCH-LIMITED |
GH-RESEARCH-LIMITED-GH-RESEARCH-LIMITED |
62%
|
d reduce the earnings per share, which could have a material adverse effect on the price of shares. We may be at an increased risk of securities class action litigation. Historically, securities clas… |
| LYNX1-CAPITAL-MANAGEMENT-GP-LLC |
LYNX1-CAPITAL-MANAGEMENT-GP-LLC |
62%
|
ion of outstanding options, (4) make payment of a cash settlement to the participants equal (per share) to the amount to be paid for one share under the agreement of merger or takeover, or (5) vary t… |
| PRICEWATERHOUSECOOPERS-INTERNATIONAL-LIMITED |
PRICEWATERHOUSECOOPERS-INTERNATIONAL-LIMITED |
62%
|
and the associated strengthening or weakening of those foreign currencies throughout the year. In the year ended December 31, 2024, the foreign exchange gain primarily related to the U.S. dollar cash… |
| TRADING-FUND-OS-BVF-GP-HOLDINGS |
TRADING-FUND-OS-BVF-GP-HOLDINGS |
62%
|
ion of outstanding options, (4) make payment of a cash settlement to the participants equal (per share) to the amount to be paid for one share under the agreement of merger or takeover, or (5) vary t… |
| VOTING-INTEREST-MAIN-ACTIVITIES-GH-RESEARCH-IREL |
VOTING-INTEREST-MAIN-ACTIVITIES-GH-RESEARCH-IREL |
62%
|
e FCA. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The… |
